The ambitious '95-95 by 2025' roadmap for the diagnosis and management of fungal diseases

Thorax

Volumn 70, Issue 7, 2015, Pages 613-614

  Denning, David W ^a,b,c  

^a Global Action Fund for Fungal Infections   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA; BLASTOMYCOSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCCIDIOIDOMYCOSIS; COMPUTER ASSISTED TOMOGRAPHY; DERMATOMYCOSIS; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS CANDIDIASIS; FUNGUS CULTURE; HEALTH CARE ACCESS; HISTOPLASMOSIS; HUMAN; IMMUNOASSAY; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; LUNG MYCOSIS; MICROSCOPY; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRICK TEST; PRIORITY JOURNAL; SERODIAGNOSIS; SOUTH AMERICAN BLASTOMYCOSIS; THRUSH; TUBERCULOSIS; DISEASE MANAGEMENT; INTERNATIONAL COOPERATION; LUNG DISEASES, FUNGAL; RESPIRATORY TRACT EXAMINATION; TRENDS;

ANTIFUNGAL AGENTS; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; DISEASE MANAGEMENT; HUMANS; INTERNATIONAL COOPERATION; LUNG DISEASES, FUNGAL;

EID: 84939240357     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207305     Document Type: Article

References (14)

1. Global Action Fund for Fungal Infections. 95-95 by 2025. Improving outcomes for patients with fungal infections across the world: a roadmap for the next decade. May 2015. http://www.gaffi.org/roadmap/
2. GAFFI recognises world AIDS day, by applying for itraconazole to be included on Essential Medicines List. http://www.gaffi.org/gaffi-recognises-world-aids-day-by-applying-for-itraconazole-to-be-included-on-essential-medicines-list/
3. Kelmenson VA Treatment of pulmonary aspergillosis. Dis Chest 1959; 36: 442-3.
4. Greendyke RM, Kaltreider NL. Chronic histoplasmosis; report of a patient successfully treated with amphotericin B. Am J Med 1959; 26: 135-8.
5. Brown GD, Denning DW, Gow NAR, et al. Human fungal infections: the hidden killers. Sci Transl Med 2012; 4: 165rv13.
6. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2095-128.
7. Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS ONE 2014; 9: e98502.
8. Global Action Fund for Fungal Infections. Reduction in AIDS and TB deaths by a million a year, key actions and modelling. http://www.gaffi.org/wp-content/uploads/Appendices-7-V3.pdf
9. Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16: 870-7.
10. Xu H, Li L, Huang WJ, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect 2012; 18: 403-8.
11. Ogawa H, Fujimura M, Takeuchi Y, et al. Sensitization to Bjerkandera adusta enhances severity of cough symptom in patients with fungus-associated chronic cough (FACC). Med Mycol J 2011; 52: 205-12.
12. Chrdle A, Mustakim S, Bright-Thomas RJ, et al. Aspergillus bronchitis without significant immuno-compromise. Ann N Y Acad Sci 2012; 1272: 73-85.
13. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012; 25: 297-317.
14. Vargas SL, Ponce CA, Gallo M, et al. Near-universal prevalence of Pneumocystis and associated increase in mucus in the lungs of infants with sudden unexpected death. Clin Infect Dis 2013; 56: 171-9.